The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression
Open accessAbstract
Stimulation of the interleukin-6 (IL-6) signalling pathway occurs via the IL-6 receptor–glycoprotein 130 (IL-6R–gp130) receptor complex and results in the regulation of acute-phase protein genes in liver cells. Ligand binding to the receptor complex leads to tyrosine phosphorylation and activation of Janus kinases (Jak), phosphorylation of the signal transducing subunit gp130, followed by recruitment and phosphorylation of the signal transducer and activator of transcription factors STAT3 and STAT1 and the src homology domain (SH2)-containing protein tyrosine phosphatase (SHP2). The tyrosine phosphorylated STAT factors dissociate from the receptor, dimerize and translocate to the nucleus where they bind to enhancer sequences of IL-6 target genes. Phosphorylated SHP2 is able to bind growth factor receptor bound protein (grb2) and thus might link the Jak/STAT pathway to the ras/raf/mitogen-activated protein kinase pathway. Here we present data on the dose-dependence, kinetics and kinase requirements for SHP2 phosphorylation after the activation of the signal transducer, gp130, of the IL-6-type family receptor complex. When human fibrosarcoma cell lines deficient in Jak1, Jak2 or tyrosine kinase 2 (Tyk2) were stimulated with IL-6–soluble IL-6R complexes it was found that only in Jak1-, but not in Jak 2- or Tyk2-deficient cells, SHP2 activation was greatly impaired. It is concluded that Jak1 is required for the tyrosine phosphorylation of SHP2. This phosphorylation depends on Tyr-759 in the cytoplasmatic domain of gp130, since a Tyr-759 → Phe exchange abrogates SHP2 activation and in turn leads to elevated and prolonged STAT3 and STAT1 activation as well as enhanced acute-phase protein gene induction. Therefore, SHP2 plays an important role in acute-phase gene regulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In response to IL-6 SHP2 is rapidly recruited to gp130 [8] and phosphorylated by JAKs [11], which hints to a function as early feedback inhibitor.”
From The tyrosine phosphatase SHP2 increases robustness and information transfer within IL-6-induced JAK/STAT signalling (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The lack of influence of SHP2 on robustness of late IL-6-induced STAT3 activation (Fig. 4) might be explained by the fact that SHP2 itself is phosphorylated rapidly in response to IL-6 (Fig. 1b) which causes dissociation from gp130 [9–11].”
From The tyrosine phosphatase SHP2 increases robustness and information transfer within IL-6-induced JAK/STAT signalling (2021) · cites this paper as [11]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
Self-citationZhong, Z., Wen, Z., & Darnell, J. E. (1994) · Science · doi:10.1126/science.8140422 · Cited by 2,070
Research works printed but not linked: 3
- Nicola, N. A. (1994) in Guidebook to Cytokines and their Receptors (Nicola, N. A., ed.), pp. 1-7, Oxford University Press, Oxford
- Murakami, M., Narazaki, M., Hibi, M., Yawata, H., Yasukawa, K., Hamaguchi, M., Taga, T. and Kishimoto, T. (1991) Proc. Natl. Acad. Sci. U.S.A. 88, 11349-11353
- Heinrich, P. C., Behrmann, I., Graeve, L., Gro$ tzinger, J., Haan, S., Horn, F., Horsten, U., Kerr, I. M., May, P., Mu$ ller-Newen, Schaper, F., Terstegen, L. and Thiel, S. (1998) in Signalling in the Liver (Ha$ ussinger, D. and Heinrich, P. C., eds.), pp. 55-71, Kluwer Academic Publishers, Dordrecht/Boston/London
Cited by
Sorted by citations
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272
Self-citationIL-6 in inflammation, autoimmunity and cancer
Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453
“The enhanced STAT3 activation was initially considered the result of an inability to recruit SHP-2, a negative regulator having tyrosine phosphatase activity (113–115).”
BackgroundThe role of IL-6 and STAT3 in inflammation and cancer
Hodge, D. R., Hurt, E. M., & Farrar, W. L. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.016 · Cited by 966
“In addition to these proteins, there are phosphatases that attenuate signals in the classic sense of removing phopho-signals from activating sites of kinases [82–85].”
BackgroundSignal Transducer and Activator of Transcription‐3, Inflammation, and Cancer
Aggarwal, B. B., Kunnumakkara, A. B., Harikumar, K. B., Gupta, S. R., Tharakan, S. T., Koca, C., Dey, S., & Sung, B. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04911.x · Cited by 663
STAT proteins: novel molecular targets for cancer drug discovery
Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1204086 · Cited by 643
“…SHP-2, as well as a protein serine/threonine phosphatase, PP2A, are strongly implicated in STAT signaling, including Stat1, Stat3 and Stat5 (Ram and Waxman, 1997; Schaper et al., 1998; Shuai et al., 1996b; Stofega et al., 1998; Strehlow and Schindler, 1998; Woetmann et al., 1999; Yu et al., 2000).”
Background
Metadata
- Authors
- SCHAPER, F., GENDO, C., ECK, M., SCHMITZ, J., GRIMM, C., ANHUF, D., KERR, I. M., & HEINRICH, P. C.
- Affiliations
- RWTH Aachen University (DE)
- Department of Biochemistry, RWTH-Aachen, Pauwelsstraße 30, D52057 Aachen, Germany
- Imperial Cancer Research Fund, 44 Lincoln's Inns Field, London WC2A 3PX, U.K.
- Corresponding author
- SCHAPER, Fred
- GENDO, Cornelia
- SCHMITZ, Jochen
- GRIMM, Carsten
- ANHUF, Dirk
- ORCID
- SCHAPER, Fred
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 1998-11-01
- Volume
- 335
- Issue
- 3
- Pages
- 557-565
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- PMC
- PMC1219816
- OpenAlex
- W1939561089
- Cited by
- 178
- References
- 43
- Citations by year
- 2026: 1 · 2024: 5 · 2023: 1 · 2022: 2 · 2021: 5 · 2020: 7 · 2019: 7 · 2018: 4 · 2017: 6 · 2016: 5 · 2015: 4 · 2014: 8 · 2013: 5 · 2012: 6
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Biochemical Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutscher Akademischer Austauschdienst
- Deutsche Forschungsgemeinschaft
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- SHP2, protein tyrosine phosphatase, gp130, IL-6 signaling, JAK1, JAK2, TYK2, STAT3, STAT1, acute phase proteins, tyrosine phosphorylation, Grb2, RAS/RAF/MEK pathway, hepatic gene expression, fibrosarcoma cells
- MeSH terms
- DNA-Binding Proteins, Enzyme Activation, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Membrane Glycoproteins, Protein-Tyrosine Kinases, Proteins, Proto-Oncogene Proteins, Recombinant Fusion Proteins, Tumor Cells, Cultured, Signal Transduction, Trans-Activators, Antigens, CD, Interleukin-6, Mutagenesis, Site-Directed, Protein Tyrosine Phosphatases, src Homology Domains, Receptors, Interleukin-6, Intracellular Signaling Peptides and Proteins, STAT3 Transcription Factor, Cytokine Receptor gp130, Janus Kinase 1, Janus Kinase 2, TYK2 Kinase, Protein Tyrosine Phosphatase, Non-Receptor Type 6, Protein Tyrosine Phosphatase, Non-Receptor Type 11, SH2 Domain-Containing Protein Tyrosine Phosphatases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review